Wound dressing compositions
View Patent ↗A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.
1. A wound dressing composition comprising a therapeutically effective concentration of a non-viable whole cell lysate or releasate of a macrophage that increases fibroblast proliferation compared to a control dressing composition that lacks the non-viable whole cell lysate or releasate, wherein the non-viable whole cell lysate or releasate comprises protease inhibitors that are secreted by the macrophage during its normal growth cycle.
2. The wound dressing composition according to claim 1 , wherein the non-viable whole cell lysate or releasate is dispersed in or on a pharmaceutically acceptable vehicle.
3. The wound dressing composition according to claim 2 , wherein the pharmaceutically acceptable vehicle is in the form of a solid sheet, a semi-solid ointment, an apertured solid sheet, a web, a woven fabric, a knitted fabric, a nonwoven fabric, a hydrophilic foam, a freeze-dried sponge or a solvent-dried sponge.
4. The wound dressing composition according to claim 3 , wherein the pharmaceutically acceptable vehicle comprises a bioabsorbable freeze-dried sponge.
5. The wound dressing composition according to claim 1 , wherein the non-viable whole cell releasate or lysate is dispersed in or on a solid vehicle that either comprises, or consists essentially of, a solid bioabsorbable material selected from the group consisting of collagen, chitosan, oxidized cellulose, or mixtures thereof.
6. The wound dressing composition according to claim 1 which is substantially dry.
7. The wound dressing composition according to claim 1 , wherein the composition further comprises from about 0.01 to about 10% by weight on a dry weight basis of one or more wound healing therapeutic substances.
8. The wound dressing composition according to claim 1 which is substantially sterile.
9. The wound dressing composition according to claim 1 , wherein the non-viable whole cell lysate or releasate increases fibroblast proliferation in a chronic wound environment.
10. A wound dressing composition comprising a non-viable whole cell lysate of a macrophage, the composition comprising a mixture of proteins, glycoproteins, polysaccharides, lipids and nucleic acids present intracellularly in the macrophage and secreted extracellularly from the macrophage.
11. The wound dressing composition according to claim 10 , wherein the non-viable whole cell lysate is dispersed in or on a bioabsorbable freeze-dried sponge.
12. The wound dressing composition according to claim 10 , wherein the non-viable whole cell lysate is dispersed in or on a pharmaceutically acceptable vehicle.
13. The wound dressing composition according to claim 12 , wherein the pharmaceutically acceptable vehicle is in the form of a solid sheet, a semi-solid ointment, an apertured solid sheet, a web, a woven fabric, a knitted fabric, a nonwoven fabric, a hydrophilic foam, a freeze-dried sponge or a solvent-dried sponge.
14. The wound dressing composition according to claim 10 , wherein the non-viable whole cell lysate is dispersed in or on a solid vehicle that either comprises, or consists essentially of, a solid bioabsorbable material selected from the group consisting of collagen, chitosan, oxidized cellulose, or mixtures thereof.
15. The wound dressing composition according to claim 10 which is substantially dry.
16. The wound dressing composition according to claim 10 , wherein the wound dressing composition further comprises from about 0.01 to about 10% by weight on a dry weight basis of one or more wound healing therapeutic substances.
17. The wound dressing composition according to claim 10 which is substantially sterile.